Like many trade shows, conferences and other events this year, the American Society of Gene & Cell Therapy (ASGCT) had to quickly make alternative arrangements for its annual meeting due to COVID-19. To avoid cancelling this highly anticipated event, organizers opted for a virtual conference for speakers, exhibitors and attendees.
Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.
Starting out, Aldevron founders Michael Chambers and John Ballantyne had one thing in common besides being fascinated with biotechnology and its applications in health care. They are both graduates of North Dakota State University (NDSU) in Fargo.